Medical & Biological Engineering & Computing

, Volume 56, Issue 4, pp 547–569 | Cite as

Continuous remote monitoring of COPD patients—justification and explanation of the requirements and a survey of the available technologies

  • Ivan Tomasic
  • Nikica Tomasic
  • Roman Trobec
  • Miroslav Krpan
  • Tomislav Kelava
Open Access
Review Article


Remote patient monitoring should reduce mortality rates, improve care, and reduce costs. We present an overview of the available technologies for the remote monitoring of chronic obstructive pulmonary disease (COPD) patients, together with the most important medical information regarding COPD in a language that is adapted for engineers. Our aim is to bridge the gap between the technical and medical worlds and to facilitate and motivate future research in the field. We also present a justification, motivation, and explanation of how to monitor the most important parameters for COPD patients, together with pointers for the challenges that remain. Additionally, we propose and justify the importance of electrocardiograms (ECGs) and the arterial carbon dioxide partial pressure (PaCO2) as two crucial physiological parameters that have not been used so far to any great extent in the monitoring of COPD patients. We cover four possibilities for the remote monitoring of COPD patients: continuous monitoring during normal daily activities for the prediction and early detection of exacerbations and life-threatening events, monitoring during the home treatment of mild exacerbations, monitoring oxygen therapy applications, and monitoring exercise. We also present and discuss the current approaches to decision support at remote locations and list the normal and pathological values/ranges for all the relevant physiological parameters. The paper concludes with our insights into the future developments and remaining challenges for improvements to continuous remote monitoring systems.

Graphical abstract


Remote patient monitoring Telehealthcare Telemedicine Telehealth eHealth Chronic obstructive pulmonary disease COPD Patch ECG Transcutaneous measurement Decision support in healthcare 

1 Introduction

According to the World Health Organization (WHO) [1], chronic obstructive pulmonary disease (COPD) is currently the fourth, and will soon become the third, most frequent cause of death worldwide. It is also a disabling disease and therefore associated with high costs for treating and managing patients.

At the same time, it is well known that remote patient monitoring can significantly reduce healthcare costs [2]. Such remote monitoring is very applicable to COPD patients, and there is evidence that it reduces costs [3] by at least 14% [4]. However, there are still no widely accepted remote monitoring services involving recently developed sensors that use available technologies efficiently. Currently, COPD patients’ physiological parameters are not continuously monitored outside hospitals, except for research purposes. Symptoms are typically reported by the patients themselves using paper-based diaries.

COPD patients are usually outpatients, except in cases of exacerbation (sudden worsening of their health status, which happens on average one to four times per year), for which they might be hospitalized. More than 70% of COPD-related healthcare costs are consequences of emergency and hospital stays for the treatment of exacerbations [5]. On the other hand, remote monitoring can reduce the frequency and severity of COPD exacerbation symptoms [6], and consequently reduce the costs. Moreover, there are studies that investigate the suitability of home care for severe, uncomplicated exacerbations [7].

Even though economic aspects are important, the primary goal of remote monitoring is an improvement in the level of care. Based on 10 trials, McLean et al. showed in a Cochrane systematic review that telehealthcare can increase the quality of life for COPD patients, estimated by the St. George’s Respiratory Questionnaire (SGRQ) [8], and reduce the number of exacerbations and emergency hospitalizations [9]. The authors defined the term telehealthcare as follows: “healthcare at a distance, involving the communication of data from the patient to the health caregiver, usually a doctor or nurse, who then processes the information and responds with feedback about the management of the illness.”

The terms telemonitoring and telemedicine are probably the most often used synonyms for telehealthcare, even though the term telemedicine most often refers only to communications between healthcare providers [10]. The two terms are used by Paré et al. [11, 12] and Bashshur et al. [13], respectively, in their reviews that demonstrate the usefulness of remote monitoring in chronic diseases in general. A recent review by Lundell et al. showed evidence that “telehealthcare may lead to improvements in physical activity level” for COPD patients [14].

A review by Pedone and Lelli [15], including an investigation involving 256 patients in the UK [16] that employed SGRQ and oxygen saturation monitoring, showed the positive but not significant effect of telehealthcare on hospital admissions and emergency room (ER) visits. In agreement, McDowell et al. [17] showed that home-based healthcare with telemonitoring improves the SGRQ score, but did not provide any significant improvement in ER visits, hospital admissions, and exacerbations, and was not even cost effective.

In conclusion, the evidence for telehealthcare’s effectiveness is mixed and not conclusive, but the studies in general show an improvement or at least an equivalence with the standard care, without differences in mortality rates (except for the review by Polisena et al. [18], which showed higher mortality rates in the “telephone-support” group).

These studies of telehealthcare focus mostly on the use of communication technologies, like telephone and internet, to communicate with healthcare professionals from home, instead of the usual face-to-face care, whereas the physiological data and symptom self-reporting are transmitted and analyzed on a daily basis. As such, telehealthcare is a subset of “remote monitoring” as we define it, which also encompasses automatic continuous physiological data transmission and processing, decision support, the prediction of deteriorations, and alarming. Therefore, we can expect that remote monitoring, as it develops over time and involves more measured parameters and more sophisticated decision support algorithms, will be more efficient than telehealthcare is today.

In recent years, the developments in remote monitoring solutions have been intensive. Consequently, there are a number of different devices that can be used for monitoring the physiological, behavioral, and environmental parameters for COPD patients [19]. However, there are still various challenges when it comes to obtaining all the significant sensory inputs, and about how to merge and fuse the data coming from different sources and sensors, for the purposes of providing the input to a decision support system that should provide efficient early detection, prediction, and alarms for medical personnel or other healthcare providers. The most important task of any alarm system is to detect common life-threatening events in a timely manner, in order that an effective treatment is possible.

We see four possibilities with respect to the remote monitoring of COPD patients: (1) continuously monitoring during normal daily activities for the early detection of exacerbations and life-threatening events, (2) during the home treatment of mild exacerbations, (3) for monitoring oxygen therapy, and (4) for monitoring exercise.

With respect to the technology used, most of the previous efforts related to enabling the remote monitoring of COPD patients focused on using the self-reporting of symptoms, pulse oximetry, and spirometry [20, 21]. Medical justifications for the choices in sensory inputs will be explained in the continuation, together with the current state of the art. Pulse oximeters, however, cannot detect changes in the arterial carbon dioxide (CO2) partial pressure (PaCO2), which we argue is one of the most significant parameters for COPD patients. The PaCO2 is currently obtained invasively by taking blood samples at discrete time instants. To motivate an improvement, this paper justifies PaCO2 monitoring for COPD patients continuously and noninvasively by transcutaneous CO2 measurements (PtcCO2). We also discuss and justify the role of cardiac electrical activity, i.e., electrocardiogram (ECG) monitoring. PtcCO2 and ECG have not been used significantly so far, even though they are two crucial physiological parameters for the remote monitoring of COPD patients. There are currently specific scientific and technological challenges for the continuous remote monitoring of the PtcCO2 and ECG, which will also be discussed and explained in the continuation.

2 Chronic obstructive pulmonary disease—a short description for engineers

COPD is a chronic and progressive respiratory disease for which there is no cure for the cause of the disease, but there are a number of therapeutic approaches for relieving the symptoms and slowing the progression of the disease. It presents as a combination of signs and symptoms, of which breathlessness, excessive sputum production, reduced exercise tolerance, and a chronic cough are the most common. The main causes of COPD are tobacco smoke (the prevalent cause), respiratory infections, air pollution, dust, and chemicals in poorly ventilated areas.

The pathology of COPD affects the large airways, the small (peripheral) bronchioles, and the lung tissue itself. The normal inflammatory response in the aforementioned clinical conditions is amplified in people prone to COPD development. The pathophysiologic mechanisms are not clear and are most likely diverse. Increased numbers of activated polymorphonuclear leukocytes and macrophages release elastases, the enzymes responsible for degradation, in a manner that cannot be counteracted effectively, resulting in destruction of the lung [22]. As a consequence of the destroyed alveolar walls, the total respiratory surface area responsible for gas exchange is reduced. In addition, the increased airflow resistance in the large and small airways causes difficulties with breathing, air trapping in the lung, and hyperinflation of the lung. The air trapped within the destroyed lung forms large air pockets that are poorly ventilated (areas with perfusion but no ventilation). The impaired regional ventilation causes a ventilation-perfusion (V/Q) mismatch.

Easily noticeable physiological consequences are difficulties in exhaling and breathlessness. In patients with severe COPD, poor sleep quality is often reported [23]. Exacerbation episodes are important and are the triggers for bacterial or viral infections, necessitating antibiotic treatment.

In patients that smoke, the cessation of tobacco use is mandatory. In fact, this is the only intervention that definitely slows the development of COPD. When the disease is diagnosed, vaccination against influenza and pneumococcal pneumonia is recommended, since influenza is the most important cause of excess mortality. As an anti-inflammatory treatment for patients with frequent exacerbations, inhaled or oral corticosteroids are usually prescribed for short intervals. A possible additional therapy is pulmonary rehabilitation (a comprehensive program that combines exercise training, smoking cessation, nutrition counseling, and education) followed by a home exercise program and/or by repeated pulmonary rehabilitations.

Another common therapeutic intervention is home oxygen admission, each day for at least 15 h, to ensure the maximum benefit [24] (also during sleep), or at least during planned exercise, where there is evidence that it improves exercise performance [25] and endurance [26]. This long-term oxygen therapy (LTOT) improves the survival rates for COPD patients with low arterial oxygen partial pressure (PaO2) (less than 7.3 kPa (55 mmHg)) [27]. LTOT can improve outcomes other than mortality, including quality of life, cardiovascular morbidity, depression, cognitive function, exercise capacity, and frequency of hospitalization [28]. Oxygen in LTOT is delivered to the nose with nasal cannulas (prongs). The drawbacks of LTOT are that it additionally reduces the mobility of patients, can increase levels of CO2 in the blood stream, and entails a risk of burns and starting fire for patients who continue to smoke, since oxygen supports burning [29].

To prevent death from a lack of oxygen, oxygen is also commonly administrated in acute COPD exacerbations, most often by means of non-invasive ventilation (NIV), which in contrast to LTOT provides a positive pressure during breathing, and is therefore delivered by a mask over nose and mouth [30]. Another indication for NIV (or even invasive ventilation) is the exhaustion that can be caused by increased work of breathing.

2.1 Oxygen levels and carbon dioxide retention in patients with COPD

CO2 and O2 are the gases exchanged between the blood and the inhaled air during respiration, with CO2 diffusing approximately 20 times faster than O2. The exchange of gases is compromised in COPD because of the destroyed airways and lung tissue, which appears as the ventilation/perfusion ratio (V/Q) mismatch. As a consequence of respiratory failure, either only the PaO2 is decreased, or both the PaO2 and PaCO2 are abnormal (low PaO2—hypoxemia, high PaCO2—hypercapnia).

The gold standard for obtained blood-gas partial pressures and saturations is the arterial blood gas test (ABG), which involves taking an arterial blood sample and is therefore invasive. Oxygen levels are routinely measured noninvasively by pulse oximetry, which provides continuous peripheral O2 saturation (SpO2). The SpO2 is usually approximately equal to the arterial oxygen saturation (SaO2) that is obtained by ABG (the typical difference is < 2% [31]). The SaO2 and PaO2 are directly related through the oxygen–hemoglobin dissociation curve (ODC), which is not fixed and can vary even for the same person, not only depending on the temperature, PaCO2, and pH but also depending on some pathological conditions [31]. On the other hand, PaCO2 is routinely estimated noninvasively from the exhaled breath (end-tidal CO2 pressure (PetCO2)).

The PetCO2, however, is not a reliable estimate of the PaCO2 for COPD patients because of physiological reasons [32, 33], and because the gas needs to be sampled directly at the patient’s airways [34] which is practically hard to accomplish. Fortunately, novel research shows that it is possible to reliably estimate the PaCO2 and even PaO2 from transcutaneous monitoring [33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46] (PtcCO2 and PtcO2, respectively), which is not affected by the COPD specificities and is therefore reliable for COPD patients. In fact, PtcCO2 has recently become the preferred method for estimating PaCO2 in remote settings [32, 33].

Oxygen is commonly administered to patients during LTOT, but more importantly in acute exacerbations, which saves lives by preventing severe hypoxemia. Oxygen therapy can, however, increase the PaCO2, as explained in the next paragraph. In fact, about a quarter of COPD patients with acute exacerbations are at risk of hypercapnia if they are given a high dose of oxygen [47].

It might seem absurd at first glance that oxygen therapy can cause hypercapnia, but there are several mechanisms responsible for this effect [47]. Here, we mention the most influential:
  • Oxygen-induced deterioration of V/Q matching (see Fig. 1). As was already mentioned before, COPD is characterized by V/Q mismatching. There is, however, a physiological mechanism that is correcting the V/Q ratio: for alveoli with reduced ventilation (thus reduced alveolar pO2—partial pressure of oxygen), pulmonary capillaries supporting these alveoli will constrict, reducing perfusion for the alveoli with reduced ventilation, and consequently improving the V/Q match. In other words, the delivery of blood is reduced to poorly ventilated parts of the lung, causing more blood to go to areas where the gases can be more efficiently exchanged. This mechanism is called hypoxic pulmonary vasoconstriction. The most influential factor for hypoxic pulmonary vasoconstriction is alveolar pO2. During the oxygen therapy, the pO2, even in alveoli with low ventilation, will increase, inhibiting hypoxic pulmonary vasoconstriction. As a result, alveoli with relatively impaired ventilation will be well perfused, leading to an increase in V/Q mismatch [48]. Put more intuitively, a perfusion increase in the lung areas that are purely ventilated will decrease the efficiency of the gas exchange and cause an increase in PaCO2.
    Fig. 1

    Hypoxic pulmonary vasoconstriction and its inhibition by oxygen therapy. a Normal alveolar ventilation and perfusion. b Reduced ventilation in the darker alveolus (thus, the local pO2 also drops) causes reduced perfusion. c Oxygen therapy increases pO2 in all the alveoli, including the dark one, and inhibits hypoxic pulmonary vasoconstriction

  • Another mechanism for oxygen-induced hypercapnia is the Haldane effect, which refers to the increased capacity of deoxygenated hemoglobin to bind and carry CO2, compared to the oxygenated form. Thus, when there is an abundance of O2, CO2 is released into the blood stream, causing the PaCO2 to rise [48].

  • People with healthy lungs have breathing regulation dependent mostly on changes in blood CO2 levels. Since some patients with COPD have high levels of CO2 for long periods of time, the brain’s regulatory breathing center can, over time, become less sensitive to CO2 levels, and more dependent on O2 levels, which causes these patients to rely more on a low arterial O2 level to stimulate their breathing. This means that oxygen therapy can reduce the stimulus to breathe. As a consequence of this reduced breathing, CO2 removal from the lungs is decreased. This “hypoxic drive” theorem was traditionally widely accepted, but it was recently challenged at least for the acute situation, as having only a time-limited effect on ventilation that cannot explain the total increase in PaCO2 [48].

Hypercapnia can cause various symptoms, ranging from mild headaches, lethargy, and confusion, to severe ones with a hypnotic effect and acidosis with subsequent organ dysfunction, which can lead to coma and death [47, 49]. It also decreases diaphragm contractility and favors muscle fatigue [50]. Clinical signs of hypercapnia are as follows [47]: vasodilation producing flushing and warm peripheries with dilated blood vessels (including retinal veins), a bounding pulse (a pulse that feels full and spring-like on palpation as a result of an increased thrust of cardiac contraction or an increased volume of circulating blood within the elastic structures of the vascular system), drowsiness, flapping tremor, confusion, and coma.

To decrease the risk of hypercapnia induced by oxygen therapy in acute situations, current clinical guidelines recommend that all patients with COPD receive oxygen therapy targeted at 88–92% SpO2 until hypercapnia is excluded by an ABG analysis within 1 h of the treatment being started [24, 47]. For some patients, even very small amounts of supplemental oxygen are sufficient to worsen hypercapnia, so they might need an even lower target saturation range [47]. On the other hand, if the PaCO2 is normal, oxygen therapy can target the usual saturation range of 94–98% and so be more efficient [47].

For the purpose of keeping the SaO2 within a desired range, pulse oximeters are used in a closed loop to correct for the administrated oxygen levels. There is clear evidence that this titrated, and therefore closely regulated, acute oxygen therapy reduces the mortality and hypercapnia, compared to non-titrated oxygen therapies [24, 51].

LTOT is also initially titrated for specific needs of each patient but not during the therapy. The goal of the initial titration is to reach SpO2 > 90% (resting PaO2 > 8 kPa (60 mmHg)) without a significant rise in CO2 [52]. This is done by the ABG analysis, but transcutaneous measurements can also be used [52].

Although it is widely accepted that oxygen-induced hypercapnia can develop during COPD exacerbations, few studies have reported on PaCO2 changes during LTOT. Cooper et al. reported a mean PaO2 increase of 3 kPa, and a mean PaCO2 increase of 0.39 kPa, while patients were breathing oxygen (30% concentration) [53]. Török et al. showed increase in PaCO2 during incremental increase of oxygen flow in the initial adjustment of LTOT but the “rise in CO2 was not considered to be high enough to lead to a lower prescription of oxygen” [54]. During sleep, however, physiological changes occur that cause the SpO2 to drop for the patients with COPD (nocturnal oxygen desaturation (NOD)). Since hypoxemia has effects on the cardiovascular system, NOD could possibly also be a reason why COPD patients die more during the night [23]. To counteract NOD, there is a recommendation, inconsistently applied around the world [55], to increase oxygen flow by 1 l/min during sleep and during exercise (to counteract the increased need for oxygen during exercise) [23]. At least one study has reported a significant increase in PaCO2 due to this increase in oxygen flow [56]. Therefore, at least during sleep, patients could benefit from titrated LTOT, much like for acute oxygen therapy, but the patients should also be monitored for hypercapnia [23].

Even though NIV at home is currently not explicitly recommended for COPD patients [30, 57], it is used instead of LTOT for specific patients especially in some geographic areas [58]. In contrast to LTOT, transcutaneous CO2 measurement was studied for NIV at home as an alternative to ABGs for adjusting NIV settings and was found appropriate [33, 35, 41, 59].

2.2 Relation between COPD and cardiac problems

If low oxygen levels are present for longer periods of time (chronic hypoxemia), they can result in hypoxic pulmonary vasoconstriction (Fig. 1). On the other hand, the destruction of lung tissue leads to a breakdown of the pulmonary capillaries, and hence a reduction of the pulmonary vascular system. These two mechanisms cause an increased resistance of the pulmonary vascular system to the blood stream. The increased resistance causes an increase in the pulmonary artery pressure and makes it harder for the heart to pump blood to the lungs. If this condition continues, it can cause the heart muscle to grow in size (right ventricular hypertrophy) and eventually lead to failure of the right side of the heart [60].

It takes time to develop right-side heart failure, but the heart remodeled with hypertrophy, and receiving hypoxemic blood for its own nutrition, is very prone to arrhythmias and sudden cardiac events. On the other hand, hypercapnia decreases myocardial contraction [61] and also predisposes to arrhythmias [62]. Furthermore, COPD occurs frequently with coronary artery disease [63]. For all these reasons, a substantial proportion of the deaths in patients with COPD is the result of cardiovascular complications [63, 64, 65].

In general, cardiovascular diseases are the most frequent comorbidities with COPD and include the following entities: coronary artery disease, heart failure (about 30% of patients with stable COPD show some degree of heart failure), arrhythmias, and hypertension (one of the most frequent comorbidities in COPD) [63, 66].

2.3 Physical activity in COPD

Regular physical activity (PA) is recommended for all patients with stable COPD [66]. Walking is generally accepted, but also stair-climbing, treadmill, or cycling exercises are beneficial. Pulmonary rehabilitation (supervised exercise) or a home exercise program can improve the lung’s functional status.

PA in COPD patients decreases the risk of hospitalization [67], reduces the decline in lung function [67], but can also improve the general health status and decrease both disability and mortality [68, 69].

PA is drastically reduced during and after hospitalization caused by exacerbation, but even patients with milder exacerbations, which do not require hospitalization, tend to stay indoors during the exacerbation period, which lowers PA levels [67]. It might take a number of weeks for patients to recover from exacerbation, during which time they lose muscle mass as a result of reduced activity.

Patients whose arterial PaO2 are borderline at rest may develop worsening hypoxemia during exercise, but even patients without hypoxemia may improve exercise capacity with supplementary oxygen [26]. During exercise, a substantial CO2 retention (PaCO2 increase of more than 4 mmHg) may also occur frequently in patients with COPD, and can even result in exercise-induced hypercapnia (an elevation of PaCO2 levels greater than 45 mmHg (6.0 kPa). Less frequent is a significant reduction of PaCO2 on exertion which can go even to hypocapnic levels [70].

2.4 COPD exacerbations

“An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication” [66]. In plain language, patients cannot catch their breath. Such exacerbations are the major cause of COPD patients’ hospitalization, but are also associated with deteriorations of the patients’ health-related quality of life [71], contribute to a long-term decline in lung function [72], and have an independent negative impact on the patients’ prognosis [73]. Additionally, mortality increases with the frequency of severe exacerbations, particularly if these require admission to a hospital [73].

Early recognition of exacerbation symptoms and prompt treatment improves recovery rates, reduces the risk of hospitalization, and is associated with a better health-related quality of life [74]. It is therefore beneficial to detect the first signs of exacerbations or to predict them so that the patients can be appropriately treated in a timely manner and optionally to be prioritized by home healthcare professionals. Nevertheless, if the exacerbations happen despite the preventative efforts, some of the patients, depending on the exacerbation severity, could still be treated at home for uncomplicated exacerbations [7, 75], since these exacerbations would not require an intensive investigation or complex therapy. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document [30, 66], more than 80% of exacerbations can be managed on an outpatient basis. Concordantly, the European Respiratory Society published a consensus statement stating that “most exacerbations are mild and can be treated on an outpatient basis (home care).” Severe events should be evaluated in the emergency department of a hospital, so that the patient can be admitted, if necessary. If the severity of an episode is in doubt, the assessment should take place in a hospital. In a very severe, life-threatening episode, direct admission to an intensive care unit (ICU) is indicated [76].

In the case of home care, the patients can be periodically visited by respiratory nurses who monitor treatment compliance and progress. The treatment at home can be leveraged and made more efficient and secure by using continuous remote monitoring.

3 Existing devices and technologies suitable for the remote and continuous monitoring of COPD patients

The monitoring of patients is supported by research and development in sensor technology, which has resulted in various wearable and unobtrusive sensors. These sensors are capable of monitoring physical activities and measuring physiological and biochemical parameters like electrocardiogram (ECG), heart rate (HR), blood pressure, PaO2, and body temperature [19]. There are two possibilities for unobtrusive remote monitoring: sensors can either be worn by the monitored subject or embedded in the monitored subject’s environment. Currently, noncontact sensing is prone to a low signal-to-noise ratio and is therefore not considered in this paper.

3.1 Transcutaneous O2 and CO2 monitoring

Various devices offer the possibility to simultaneously monitor the level of oxygenation and CO2, combining either SpO2 with PtcCO2 (e.g., SenTecTM, Therwil, Switzerland [37], and TCM ToscaTM, Radiometer, Neuilly Plaisance, France [77]), or transcutaneous PtcO2 with PtcCO2 (e.g., TCM Combi MTM, Radiometer, Neuilly Plaisance, France [77]).

3.2 Cardiac electrical activity (ECG) remote monitoring

Holter monitors are traditionally used for ECG acquisitions in remote settings, but they are being superseded by wireless bi-potential patch devices [78, 79, 80], whose development has been intensive in recent years (a representative example, a Savvy patch ECG sensor, is shown in Fig. 2). The patch ECG (PECG) sensors are already established as patient friendly, well tolerated, unobtrusive, wire free, and with recording capabilities that span from weeks to months (much longer than standard Holter monitors), which is beneficial for detecting potentially malignant arrhythmias that take a longer time to detect. They provide good adhesion to the skin, and some of them even claim to be waterproof.
Fig. 2

A prototype of a patch ECG monitor developed at the Jožef Stefan Institute, Ljubljana Slovenia [81, 82], with two self-adhesive disposable electrodes, a lithium coin battery, micro-processor, BT4 radio, and printed circuit board antenna (up). Savvy sensor, the final product (down)

The Savvy monitor has been certified as a medical device according to the directive MDD 93/42/EEC, and standards EN 60601 and EN ISO 14971, and has recently become available on the market, while the ZIO® XT Patch by iRhythm Technologies, Inc. and SEEQ™ MCT patch device by Medtronic, Inc. have already been extensively evaluated. The evaluations show evidence of an increased diagnostic lead in both adult and pediatric patients compared to Holters [79]. There are also other PECGs available on the market, and the number is expected to increase in the future [78, 79, 80].

3.3 Respiratory rate

One of the signs of COPD exacerbation is a respiratory rate (RR) over 25/min (see Sect. 4.7). Furthermore, there is evidence that a change in RR has a strong predictive power for exacerbation [83, 84].

The respiratory effort can be captured by an impedance pneumograph, stretch sensors, and flow thermography, which captures breathing from the temperature difference between the inhaled and exhaled air. The impedance pneumogram is the most common method used in hospitals [85]. Its basic principle is to inject current into the tissue by employing two drive electrodes placed on the chest and to measure the potential difference between the two points. The potential difference is related to the impedance of the tissue, which varies with respiration.

The respiration also affects the cardiovascular physiology. Consequently, the RR can also be estimated from the ECG and pulse oximetry. Even though it is inferior to the ECG-derived RR, pulse oximetry can also provide a reliable RR [86]. Indeed, recently, the Nellcor Respiration Rate System received CE mark approval. In addition to SpO2, and HR monitoring, it also provides RR, and all this is obtained from a single finger sensor [87].

3.4 Pulse oximetry

Pulse oximetry is the continuous measurement of saturation for peripheral oxygen (SpO2). A clip-like device is placed on a thin body part, most commonly on a finger, but also on an ear lobe, or across a foot if applied on infants. There are a number of inexpensive and easy-to-use pulse oximetry devices available on the market.

The basic principle is to emit two different wavelengths from one side of the body part using a pair of small, light-emitting diodes and measure the amount of light that passes through the body with a photodiode placed on the other side. The two wavelengths are chosen so that their absorption (the emitted minus the passed-through light) is significantly different for the oxygenized and not-oxygenized hemoglobin. The SpO2 is calculated from the ratio of the two measurements.

3.5 Nutrition and weight monitoring

Both obesity and loss of body mass are commonly encountered with COPD [76]. Malnutrition is associated with respiratory muscle dysfunction and increased mortality. Therefore, nutritional intervention should occur if a large loss of body mass is detected. Nutritional interventions aimed at achieving an ideal body weight are also recommended. High-carbohydrate diets and an extremely high caloric intake should be minimized to reduce the risk of excess CO2 production [76]. Furthermore, obesity contributes to breathlessness in some individuals due to affected diaphragm mobility. On the other hand, weight loss is associated with a more severe impairment of the lung function [76].

3.6 Blood pressure measurement

The justification for measuring blood pressure comes from the fact that hypertension is a frequent comorbidity in COPD [66], but can also be caused by corticosteroid therapy. “Blood pressure” normally refers to the arterial pressure in the systemic circulation. There are also measurements of pressures in the venous system and pulmonary vessels, but these require a catheter and are therefore beyond the scope of this paper.

The arterial blood pressure is noninvasively routinely measured by the auscultatory method involving an inflatable cuff wrapped around the arm, a manometer measuring the pressure in the cuff, and a stethoscope placed over the brachial artery at the elbow. There is also the oscilometric method, which is more suitable for automatic measurements in home environments [88]. The oscilometric method also uses a cuff. There are also continuous, noninvasive arterial pressure-monitoring devices that measure in real time, completely noninvasively and without cuffs. These devices are, however, still to prove their precision [89]. An overview of experimental blood pressure measurement devices is provided in [90].

There are a number of devices available on the market that can be used for the remote automatic monitoring of blood pressure (mostly oscilometric) that patients can use without assistance. For specific guidelines on how to measure blood pressure remotely at home, the reader can refer to [88].

3.7 Spirometry

Diagnostic spirometry measures the volumes of air inspired and expired by the lungs to assess a patient’s lung function for the purposes of comparison with a patient population or with previous measurements from the same patient. The presence of airflow limitation is recognized by a reduction in the ratio FEV1/VC or the ratio FEV1/FVC, where VC (vital lung capacity) is the maximum amount of air expired from the fully inflated lung, FVC (forced vital capacity) is the forced amount of air a person can exhale after the maximum inspiratory effort, and FEV1 (forced expiratory volume in 1 s) is the fraction of the FVC expired during the first second (see Fig. 3). The presence of a post-bronchodilator FEV1/FVC of less than 0.7 confirms the presence of COPD [66]. The FEV1/VC ratio is a relatively sensitive index of mild COPD. In moderate-to-severe cases of the disease, however, the severity of the airflow limitation is best assessed by the FEV1 in relation to reference values (also known as predicted values) [91].
Fig. 3

Representative spirograms (expired volume–time curves) for healthy subjects (FEV1/FEV ~ 4.6/5.8 = 0.8) and subjects with COPD (FEV1/FEV ~ 1.7/3.4 = 0.5)

Spirometry is used mainly in the diagnosis of COPD, as well as in the assessment of its severity, progression, and prognosis, but it is not suitable for acute states. Patients with acute severe exacerbations of COPD can be too breathless to undertake spirometry testing, but in any case, conducting spirometry in acute situations is not very informative [66].

Due to the growing number of patients, the diagnosis of COPD should take place in general practices that are equipped with spirometers. For the diagnosed patients, the spirometry should be carried out at least once per year to identify patients with a rapid decline in lung function [66]. To ensure quality, the spirometry should be carried out by nurses who have been trained in how to perform spirometry [92].

Portable handheld spirometers available on the market can be more or less accurate compared with conventional hospital-based equipment [92]. Still, the technology used in portable spirometers is constantly evolving, which means their performance is constantly improving [92]. Regardless of the device accuracy, the measurements obtained by patients on their own need to be taken with caution when supplied to a decision support system, and cannot be used as a substitute for the diagnostic spirometry [92].

Also beneficial are peak expiratory flow (PEF) meters, which are simpler and cheaper than spirometers. If we strictly apply our definition of spirometry, PEF meters are not spirometers because they measure only the maximum speed of expiration, not the volume of expired air. The PEF meters are successfully used in asthma monitoring, with high patient compliance, but they are beneficial in COPD monitoring as well. A value for PEF of less than 100 l/min is a sign of acute COPD exacerbation (see Sect. 4.7). Additionally, van den Berge et al. presented evidence that PEF is a predictive factor for exacerbation [93], whereas Inglesia et al. showed that PEF has an important predictive value for determining the risk of death in patients who required hospitalization for acute exacerbation of COPD [94].

3.8 Thermometry

Normal body function depends on a relatively constant body temperature. A body temperature higher than 38.5 °C is one of the parameters indicating severe exacerbation [76].

Most common sites used to obtain body temperature readings with medical thermometers are the anus (rectal temperature), the mouth (oral temperature), under the arm (axillary temperature), and the ear (tympanic temperature).

Oral and rectal body temperatures, although slightly different, correlate well with the core body temperature. The most easy to apply continuous temperature measurement devices in remote settings, i.e., those that can be placed on the body surface (axillary and tympanic), do not follow the core body temperature well enough to recommend their use [95].

3.9 Environmental sensors

Environmental sensors are present in the patients’ environments or are embedded into objects in the environments, like chairs, seats, mattresses, mirrors, toilet seats, and bathroom scales.

Sensors that measure environmental temperature and air quality can be used to assess the condition of patients’ living environments. There is evidence of a significant positive correlation between quality of life and air quality [96]. Air pollution has been shown to be a major COPD risk factor [97], but numerous other diseases can be caused by air pollution. Since most COPD patients are past or current smokers, it is quite informative to detect smoking. Smoking in combination with oxygen therapy is dangerous due to the risk of fire.

3.10 Personal computing devices

Data measured with physiological and environmental sensors can be preprocessed by the sensors (e.g. the R-R interval lengths can be extracted from a measured ECG). Either the results of preprocessing, or the raw signals, or both can be wirelessly transferred to the users’ personal computing devices (PCDs), such as smartphones, tablets, or smart watches. On PCDs, the data can be further processed, most importantly for detecting life-threatening events, or for some specific purposes, which in the case of an ECG can be, for example, synthesizing a 12-lead ECG [98], or extracting the breathing rate from an ECG [99]. Modern PCDs already contain a number of sensors, e.g., microphone, camera, GPS, and accelerometer. The obtained physiological signals can be integrated with the PCDs’ sensing abilities to extract relevant features that can be used as inputs for a decision support system running on the same device. From there on, the raw signals and/or the results of the processing can be forwarded to the cloud for further processing and storage [100]. The general concept of a remote monitoring system is presented in Fig. 4.
Fig. 4

General architecture of remote monitoring systems

3.11 Previous research on systems for the telemonitoring and self-management of COPD

Self-management is not universally defined, but the most general meaning of the term is the patients’ ability and skills to deal with their chronic diseases [101, 102]. In the case of self-management, patients are contacting medical professionals, whereas in telemonitoring, the communication is bidirectional and the medical personnel can initiate communication with patients or their caregivers.

A number of systems combine self-management and telemonitoring [20, 103]. Most of them focus on enabling patients to self-assess their status (see Sect. 4.5) and record pulse oximetry on their own. Some systems combine pulse oximetry with an RR sensor, blood pressure monitor, activity monitors, and less frequently some other sensors [20]. In almost all the systems, the data is transmitted on a daily basis. When a deterioration in health occurs, patients can contact the healthcare professionals or be contacted via telephone calls.

There are two available reviews covering the existing technology in COPD telemonitoring [20, 21], whereas the others, already mentioned in the introduction, focus on clinical outcomes (e.g., mortality and quality of life), reduction in healthcare service utilization, feasibility and use, and on the economic and organizational impacts of telemonitoring. Among the existing research, there is a lot of variability and a lack of consensus. For instance, different questionnaires were used as well as different threshold values for physiological parameters [21]. There is not even a consensus about what constitutes an exacerbation [104]. Efficient decision support algorithms have only been applied in a minority of studies.

The need to establish a scientifically sound methodology that is agreed on and accepted by future studies is obvious [104]. To facilitate this, in the continuation, we will identify and justify the application of the most significant technologies and sensory inputs (together with their pathological ranges) for the remote monitoring of COPD patients, review the current status of decision support systems, and present the remaining challenges.

4 Scientific and technical solutions and challenges in monitoring COPD patients

4.1 Monitoring PaCO2

Since oxygen therapy can increase PaCO2, as explained in Sect. 2.1, it is beneficial to monitor PaCO2 not only during acute oxygenation therapy but also possibly during LTOT (especially during sleep [23]) (see Sect. 2.1). Mortality in acute exacerbations of COPD was reported to be associated even with an increase in chronic stable levels of PaCO2 [51], which shows that it is also beneficial to regularly monitor stable (baseline) CO2 levels.

The standard for obtaining PaCO2 is ABG, which is an invasive procedure with risks, but also painful, time consuming, and discrete. Even though not perfectly following the PaCO2 obtained by ABG, transcutaneous monitoring has its advantages: it is painless, noninvasive, and continuous, with almost no sleep disturbance, and possibly self-manageable. It is therefore possible to use PtcCO2, along with pulse oximetry, instead of ABG, for titrating any oxygen therapy. Moreover, since PtcCO2 is continuous, the titration can be without delay.

PtcCO2 is not measured routinely in remote settings due to the lack of inexpensive PtcCO2 monitors. Even though it is likely that the prices of PtcCO2 monitors will reduce over time, as happens with all electronic devices, an open question is how to compensate for the currently high prices. One possibility is for PtcCO2 monitors to be used by medical personnel that periodically visit multiple COPD patients for the purpose of monitoring the baseline PaCO2 regularly, and/or in the minutes after the onset of oxygen therapy. This entails a need for a new software system that will keep track of each patient’s measurements and integrate them with electronic health records. Another possibility is for the same device to be shared between multiple patients for periodic use during 1 day and night. This would be enough to access how the PaCO2 changes during the LTOT, which is particularly important during the night, as explained in Sect. 2.1.

One current weakness associated with transcutaneous measurements is the approximate 2-min lag time for the PaCO2 changes to be reflected in the PtcCO2 [105]. An open scientific question is could the changes in PaCO2 be predicted to compensate for the lag?

It has been suggested that patients who are known to be at risk of hypercapnic respiratory failure should be given oxygen “alert cards” and should be instructed to show these cards to medical personnel [24, 47]. The purpose of the cards is to warn medical personnel that the patients should be given controlled rather than high-concentration oxygen therapy and to adjust the therapy based on the previous ABG results stored on the card because hypercapnic respiratory failure can occur even if the targeted SaO2 is below 88%. It is important to investigate how this digital alert card can be employed in a convenient form, like, for example, as a smartphone application, which could be accessible to medical personnel even if the patient is not capable of presenting the alert card on his/her own.

4.2 ECG, ECG-derived RR, and HR

Reports show that the primary cause of death for COPD patients is cardiac failure [64, 65]. Myocardial infarction is the co-morbidity with the greatest potential for treatment and prevention to improve the prognosis of COPD patients [64]. In general, cardiovascular diseases are the most frequent and important diseases coexisting with COPD (see Sect. 2.2.) It is therefore of the greatest importance to continuously monitor cardiac electrical activity for patients at risk, and issue alarms when dangerous event are detected.

Recent developments in ECG technology have resulted in PECGs that possess convenient features for remote monitoring (see Sect. 3.2). They are small and wireless. Patients can place them on their own, freely sleep with them, and even take a shower.

They are most often single lead devices. One lead is enough to provide HR [106] which can be used to detect arrhythmias and cardiac arrest. Some arrhythmias need to be terminated instantaneously (see Sect. 5.4); therefore, it is crucial in that situation for a system of remote monitoring to alert people in the vicinity of the patient and direct them to the nearest defibrillator (which are becoming more and more present in the environment). PECGs can also be used to obtain specific indicators, like heart rate corrected QT interval (see Sect. 5.4), relevant for COPD patients.

It has also been shown that reliable RR can be estimated from ECGs produced by them [99], which eliminates the need for separate respiratory sensors. This is of additional significance for COPD patients, since RR is one of the major parameters for detecting COPD exacerbations (see Sect. 4.7).

Figure 5 shows how RR can be extracted from amplitude-modulated ECG signal obtained using a PECG. For details of the algorithm used, see [99]. Respiration modulates the ECG also in terms of HR (respiratory sinus arrhythmia (RSA)). Even though it has been shown that extraction from HR provides a good approximation of the mean RR if the time series is longer than 1 min for young supine subjects, it is significantly less accurate for elderly people [107]. There are also other approaches for extracting the RR from ECG. For a recent evaluation of four different methods, i.e., filtering, R and RS amplitude, and QRS areas, please refer to [108].
Fig. 5

Interval of an ECG (red) measured with a patch ECG monitor, and respiration intervals (black) measured by a thermistor near the front of the nose. The amplitude of the measured ECG signal varies with respiration. All nine respiration intervals are identified (blue circles). The presented results come from a study reported in [99]

Since they are still not a part of standard clinical care (and consequently not shared among patients) and are not covered by health insurance, the disadvantage of the PECGs is that they have high cumulative consumer costs. Moreover, the customers can be dependent on the device company for raw and aggregated data retrial.

The crucial current deficiency of PECG sensors is the data-processing time, which can be after the recording (ZIO XT) or after the transmission to the company’s data networks (SEEQ), where the processing time depends on the processing abilities of the company’s data center. The Savvy sensor, however, comes with stand-alone computer software for a basic analysis of the acquired ECG that a customer can use on his/her own. The data analysis algorithms that can run directly on the PECG sensor have just recently started to be developed, an example being the HeartSaver reported in [109].

Since acute life-threatening events are the most important, it is obvious that there is a need for further developments to enable wireless monitors that can not only record ECG to estimate the arrhythmia burden but more importantly detect life-threatening events in real time and send an alarm to the relevant stakeholders for a timely diagnosis and treatment.

Even though PECG sensors detect more reportable events than Holter monitors, largely because of the significantly longer recording times, there is evidence that Holter monitors detect more events in the same period of time [79]. This might be because Holters are multichannel devices, but also due to the differences in detection algorithms. Consequently, for the PECG sensors to become a standard diagnostic tool in clinical practice, it is essential for future studies to specify the abilities of each PECG sensor and the associated detection algorithms when detecting each type of arrhythmia and conduction system disease.

The PECG sensors can potentially be used even for a 12-lead ECG synthesis [98, 110, 111]. Their additional advantage is that they can be used to obtain specific ECG leads for specific purposes [112, 113, 114].

Because of an autonomic nervous system dysfunction, COPD patients have been shown to exhibit decreased HR variability compared to control subjects, as well as reduced levels of all the linear exponents and a decreased short-term fractal exponent of the intervals between beats [115]. The power of the HR-related features for predicting exacerbations remains to be investigated.

4.3 Empowering patients and personalization

How can we make the system for the remote monitoring of COPD patients easy to use and able to adapt to each patient’s specific needs? A recent systematic review [20] shows that patients were “generally satisfied and found the systems useful to help them manage their disease and improve healthcare provision.” The review, however, indicates a number of usability problems that need to be overcome in future research. These include the short battery life, a confusing power supply, and the need to provide real-time feedback. Based on previous research by Botsis and Hartvigsen [116], the authors also emphasize that the security and confidentiality of the collected data should be satisfied. Interestingly, the authors also state that the lower compliance is related to the frequency and timing of the data collection and transmission, which is carried out at discrete time points during the day and requires effort from the patients. It is to be expected that the automatic collection and transmission of data will increase the patients’ compliance with the remote monitoring systems.

According to the study made by Gravil et al. [75], 80% of patients would be happy to be treated at home for uncomplicated exacerbations instead of being admitted to a hospital. In their study, however, the patients were visited by nurses who monitored adherence to the recommended treatment and offered reassurance, support, and education. The only measurements used were spirometry and SpO2, which were applied by the nurses. If the patients were to use a remote monitoring system on their own, we would expect the acceptance of the home treatment to be significantly lower. One of the reasons for this could be technophobia, which according to the American Telemedicine Association [117] can be reduced among users by tailoring systems to the specific needs of each user population. Furthermore, there is evidence that the promotion of easy-to-use systems and more training sessions, to make patients more familiar with the system, should improve the acceptance of these remote monitoring systems [20, 118]. Contributing to the acceptance should also be the provision of additional security that comes from the fact that the patients’ symptoms will be recognized early by the remote monitoring system and that they will be contacted and treated if any deterioration occurs.

One important goal of any COPD monitoring system should be to enable patients to better understand the disease, to familiarize themselves with symptoms and ways to control them, and to empower the patients to be more involved in their healthcare, so that they can recognize the exacerbations at an early stage.

4.4 Monitoring and controlling physical activity, exercise, and reference test

Patients with COPD have significantly lower levels of physical activity (PA) than healthy controls [119], and even lower than people with some other chronic conditions [120]. Even though PA is recommended for COPD patients (Sect. 2.3), most patients do not follow these recommendations [67]. Remote monitoring may have a positive motivating effect on COPD patients to increase PA [121, 122] by providing counseling and feedback, but it is prudent to monitor COPD patients’ physiological parameters (PaCO2, PaO2, ECG) during PA also because of the health risks involved (see Sect. 2.3). For the remote assessment of PA, both questionnaires and motion sensors, like step counters and accelerometers, can be used, but a recent investigation showed that questionnaires provide overestimates of the true PA [123].

Questionnaires are mainly used for research purposes, especially in epidemiological studies. There have been more than 15 different questionnaires developed for COPD patients [67]. From the perspective of continuous monitoring, the questionnaires can be implemented in an application for PCDs and be used by the patients on an everyday basis (see Sect. 4.5).

Pedometers are devices that count the number of steps. From the number of steps counted, it is possible to estimate not only the distance traveled but also the energy expended. However, these estimates lack precision, especially when the walking is at slow speed, which is typical in patients with COPD [67]. Despite being imprecise, there is evidence that pedometers are motivating for patients to increase and maintain their levels of PA when used alone [124], or together with a PCD application providing individualized activity goals and allowing occasional telephone contacts with caregivers [122].

Accelerometers are devices that measure acceleration. The measurements obtained with accelerometers reflect body movement. For estimating PA levels and energy expenditure, they can be combined with pedometers and physiological sensors, e.g., HR and skin temperature, to provide valid estimates of PA levels [67, 125].

It is useful to know that levels of PA cannot be accurately predicted from resting lung-function parameters, i.e., spirometry [67].

There are also reference tests for evaluating the progression of the disease. One of them is the “6-min walk test” during which the patient walks the longest distance he/she can, while his/her blood saturation is monitored with a pulse oximeter to assess exercise-induced oxygen desaturation which has an additional prognostic values besides the 6-min walk distance [70]. There is evidence of a positive association between the 6-min walking distance and the PA [67].

4.5 Self-assessment

A questionnaire implemented on a PCD can be provided to the patient to be filled in every day. They can include fields like how much coughing, how much sputum production, how much breathless—dyspnea, general feelings, PA assessment, and other questions that can be found in existing questionnaires.

The most comprehensive COPD-related questionnaires are the Chronic Respiratory Questionnaire (CRQ) [126] and the St. George’s Respiratory Questionnaire (SGRQ) [127] (online [8]). The SGRQ’s score has been associated with anxiety and depression, two major comorbidities in COPD.

The latest GOLD executive summary [30] considers CRQ and SGRQ as being “too complex to use in clinical practice” and promotes shorter measures, like the COPD Assessment test, as more suitable. Still, the questionnaires used in the research of the remote monitoring of COPD are diverse. Some of the researchers have even developed their own questionnaires [21].

A drawback of self-reporting is that it can be difficult for patients. There is evidence that only a minority of patients can “log discrete episodes of increased breathlessness, cough and purulent sputum” [128]. This is one of the reasons for preferring the continuous automatic monitoring of physiological parameters instead of self-reporting.

4.6 Monitoring medication application and adherence

An appropriate medicament therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise capacity, but “existing medications for COPD have not been shown conclusively to modify the long-term decline in lung function” [66]. In particular, exacerbations are treated with bronchodilators, systemic corticosteroids, and antibiotics, and there are new drugs developed all the time [129]. The corticosteroids can cause hypertension, which calls for blood pressure measurements and ECG monitoring during corticosteroid therapy. Stopping regular medication, such as diuretics and/or bronchodilators, on the patient’s own initiative might increase symptoms [7].

It has been suggested for more than 10 years now that remote monitoring should be used as the “gold standard” for medication adherence measurements [130], but how to effectively monitor medication compliance and how to motivate patients to take their medicaments are challenges that still remain. PCD applications that provide reminders and feedback to patients could be useful as motivators. As for monitoring compliance, intelligent packaging for medicaments, equipped with electronics for collecting and transmitting the data about usage, can provide controlled access to medicaments in terms of keeping track of how many medicaments have been used and at which times. This enables monitoring of the adherence to the therapy, the evaluation of patterns of medicament use, and monitoring the dose-response relationship [130]. Obviously, smart packaging can be tricked into tracking adherence since it is not able to detect whether the pills are actually swallowed.

Perhaps the most impressive recent development in monitoring medication adherence, which cannot be easily tricked, is the Proteus Digital Health ingestible sensor that measures medication ingestion and adherence patterns in real time [131]. It is a system of a 1-mm digestible chip and a patch that picks up the signal from the chip and can also capture the HR [132]. Another example of recent developments that are particularly significant for COPD and asthma patients is AstraZeneca’s inhaler device called Turbuhaler, which has recently been accompanied by a monitoring device to monitor the actuations of the inhaler [133].

A related problem is how to tailor medications to individual needs. According to the GOLD: “Each pharmacological treatment regime needs to be adapted to the patient (i.e., individualized), guided by the severity of the symptoms, the risk of exacerbations, comorbidities, drug availability, and the patient’s response” [66]. This can be at least partially achieved by using remote monitoring, for the purpose of titrating/adjusting the treatment, or providing patients with personalized advice. For example, in stable COPD, an increase in FEV1 following a therapeutic trial of corticosteroids for several days is often taken as an indication of regular use for these drugs [76].

4.7 Detection and classification of exacerbations

Signs are objective, whereas symptoms are subjective, evidence of a health problem.

The symptoms of severe COPD exacerbations that require hospitalization are [76]
  1. 1.

    Change in cough frequency.

  2. 2.

    Change in sputum production and appearance.

  3. 3.

    Increase in dyspnea at rest.

The signs of severe COPD exacerbations that require hospitalization are [76]
  1. 4.

    Inability to speak one full sentence.

  2. 5.

    Temperature > 38.5 °C.

  3. 6.

    Ankle oedema.

  4. 7.

    Respiratory rate > 25/min.

  5. 8.

    HR > 110/min.

  6. 9.

    PaO2 < 8 kPa [75].

  7. 10.

    Worsening cyanosis.

  8. 11.

    Use of accessory muscles.

  9. 12.

    Loss of alertness.

  10. 13.

    PEF < 100 l/min.


All of these parameters are measurable at home. Parameter 12 is significant on its own, whereas parameters 3, 7, 8, 10, and 11 are significant as a group [76]. It is important to note that the exact thresholds in the previous list are not universally accepted; studies in remote monitoring employ diverse exacerbation criteria [21], which might be one of the reasons for the inadequate performance of decision support algorithms (discussed in the next section).

The criteria for severe COPD exacerbations based on parameters that are normally measured in hospitals but can now also be measured in the home environment with portable spirometers, transcutaneous measurements, and portable ECG devices are [76] FEV1 < 1 l, PaO2 < 8 kPa (60 mmHg), SaO2 < 90%, PaCO2 ≥ 6.0 kPa (45 mmHg), and ECG abnormalities. Additional measurements for severe acute exacerbation, which are currently not measurable at home, are chest radiograph, white blood cell count ≥ 12,000, sputum stain/culture, biochemistry (electrolytes, urea, glucose, etc.). The life-threatening events are respiratory or cardiac arrest, confusion or coma, PaO2 < 6.7 kPa (50 mmHg), PaCO2 ≥ 9.3 kPa (70 mmHg), pH < 7.3.

COPD exacerbations can often be prevented [66]. It is therefore desirable to predict or at least early detect signs and symptoms of exacerbations. This can be done automatically by using decision support systems featuring the classification of patient states.

4.8 Decision support (exacerbation prediction and detection algorithms)

In most of the existing remote-monitoring systems, the information obtained is analyzed by health caregivers. Only some of them provide automatic decision support systems [15], stand-alone or in combination with human analysis. Figure 6 presents the COPD-related decision support systems data obtained from two existing reviews [20, 21], and reports featuring decision support that came after the reviews [84, 103, 134, 135, 136, 137]. The most often used inputs are the self-reporting of symptoms on a PCD, followed by pulse oximetry and spirometry (Fig. 6a). ECG has been used in only two publications: as a source of the features for exacerbation prediction [136], and to detect “clinical alert” (further details not provided) [138], whereas the PtcCO2 was not used at all.
Fig. 6

Overview of existing decision support systems. a Sensors used (Other: video/audio (five systems), physical activity (four systems), ECG (two systems), lung and heart sounds (one system), glucometer (one system)). b Patient action needed for data acquisition or automatic data acquisition. c Algorithms used. Total number of participant used in the studies is 1866, whereas the average duration of the studies was 6.4 months

Panel b shows that only about one quarter of the research featuring decision support provides automatic data acquisition. This is related to the frequency of data acquisition and analysis, which was almost exclusively on a daily basis, except in [139] where it was 3 h, in [140] where the interval could be varied depending on each patient’s needs, as well as in [136], which is the only report featuring continuous data processing. Patients’ compliance is affected by the frequency and method of data acquisition, as discussed in Sect. 4.3, but more importantly, it is not possible to detect immediate life-threatening events without continuous monitoring.

Clinical decisions are traditionally based on a set of predefined universal rules (see previous section). It is for that reason that the approach most often utilized for detecting and predicting exacerbation was by defining universal (population-based) thresholds on obtained symptoms and physiological parameters (panel c). These thresholds were sometimes adjusted to individual patients’ needs, but the best results were obtained by using more advanced classification algorithms: linear discriminant classification [141], a Bayesian network [140], a probabilistic neural network classifier [142], multilevel logistic regression [143], classification and regression trees [144], k-means clustering [145], a state machine combined with logistic regression [84], and a hybrid classifier combining a support vector machine, random forest, and a rule-based system [136]. The purpose is to classify the patient’s status as being in exacerbation (detection) or as transitional towards exacerbation, i.e., the prodromal period (prediction).

The reported accuracy in detecting exacerbations ranged from 40 to 94%, the sensitivity from 6 to 80%, and the specificity from 61 to 95%. The best accuracy in the early detection of exacerbations is reported for the hybrid classifier with 10 measured parameters and a total of 25 features used as the inputs [136]. Nevertheless, by using only self-reported symptoms as inputs, and k-means clustering, it is possible to obtain a sensitivity of 75% and 90% specificity for early exacerbation detection [145]. Furthermore, a pulse oximeter alone in combination with a classification algorithm can provide a high predictive accuracy [84].

Only two studies [142, 145] reported using patients’ electronic health records, but these were developed only for the purpose of the study and did not seem to be integrated into the patients’ standard care.

Besides completely outperforming the threshold approach and providing encouraging results, advanced classification algorithms ensure that the classification is adapted to each patient, provide ranking of features based on their predictive power [84], as well as the extraction of new rules [136]. For a concise description of the predictive analytics methods used in healthcare, the reader can refer to [21].

In addition to detecting exacerbations, it is beneficial to assess their severity for the purpose of deciding between home or hospital treatment.

4.9 Assessment of severity and deciding between home or hospital treatment

The severity of an exacerbation is assessed crudely by tachypnoea, tachycardia, the use of accessory respiratory muscles, cyanosis, and evidence of respiratory muscle dysfunction or fatigue (e.g., uncoordinated ribcage motion or paradoxical movement of the abdominal wall during inspiration) [76]. If the severity of an exacerbation is in doubt, it should always be assessed in hospital. Referral to a hospital’s emergency department is mandatory in the case of respiratory failure indicated by the increased use of accessory respiratory muscles, paradoxical movement of the abdominal wall during inspiration, and significant deterioration in mental status.

Mild exacerbations of COPD are generally believed to represent an increase in symptoms, especially dyspnea, not necessarily accompanied by increased cough and sputum production, which might be more tenacious than usual. These parameters can be obtained through a self-assessment (see Sect. 4.5). Severe exacerbation, on the other hand, is associated with acute respiratory failure, especially in patients with an impaired lung function, sometimes accompanied by hypercapnia [7], which can be obtained from a PaCO2 measurement. Severe exacerbations cannot be treated at home, so if detected, patients should be transported to a hospital.

There are no definitive clinical guidelines about whether a patient should be cared for at home or in a hospital, and physicians are often uncertain when making this decision. The most important factors are the severity of the exacerbation, acute respiratory failure, the onset of new physical signs (e.g., cyanosis, peripheral edema), and the failure of an exacerbation to respond to initial medical management [30]. Other factors that can be taken into account are cause of the exacerbation (for example, severe pneumonia), a coexisting disorder that requires admission, degree of disability, social factors like the degree of support in the community (e.g., whether the patient lives alone), patient’s history, and mental state [7, 75].

4.10 Detection of provoking and predictive factors

It is not clear which factors determine the development and severity of an exacerbation [7]:
  • It is commonly thought that viral and bacterial infections of the tracheobronchial tree are the major causes of exacerbations in the later stages of disease [129]. The role of bacterial and viral infections in COPD exacerbations is still considered as controversial by some authors [7].

  • Air pollution [66].

  • There is some evidence that ozone concentration might be slightly associated with additional hospital admissions [146].

  • Poor nutrition, i.e., malnutrition, in combination with respiratory muscle fatigue can aggravate the exacerbation.

  • Drugs (especially tranquilizers).

  • Stopping regular medication such as diuretics and/or bronchodilators on the patient’s own initiative can increase symptoms, which means that the monitoring of medication compliance is important (Sect. 4.6).

  • Inappropriate oxygen administration can aggravate an exacerbation because of a reduction in the hypoxic respiratory drive.

  • Conditions that can mimic or aggravate symptoms are pneumonia, pulmonary hypertension, heart failure or arrhythmias, pulmonary embolism, and pneumothorax.

  • The cause of about one third of severe exacerbations of COPD cannot be identified [66].

A study involving 64 patients with moderate-to-severe COPD showed evidence that chronic hypercapnic respiratory insufficiency (high PaCO2) and pulmonary hypertension are predictive factors for hospitalization caused by COPD exacerbation [147]. Long-term oxygen therapy and perhaps even long-term noninvasive mechanical ventilation at home are possibly factors that reduce the risk of severe exacerbations, since there is evidence that they reduce hospital admission in COPD with chronic hypercapnia [148].

A study using the SGRQ showed that factors for predicting frequent exacerbations were daily cough, daily wheeze (clinical sign of exhaling difficulties caused by a narrowed tracheobronchial tree), and daily cough and sputum together, and frequent exacerbations in the previous year [149]. Another study showed that SGRQ scores and poor quality of life are associated with re-admission for COPD [150].

4.11 Educational programs

Even though there are reports that educational programs for COPD patients can significantly reduce the utilization of healthcare services and improve health status [151], they have not been as actively promoted as much as programs for asthma patients [76]. Single-topic programs are available (e.g., smoking cessation, long-term oxygen therapy, rehabilitation), but there are insufficient integrated educational materials incorporating all the aspects of disease management [151].

Educational programs should improve people’s knowledge about the disease process and its treatment and should also motivate patients to change behavior and lifestyle, with the goal of improving their quality of life [151].

5 Notes about normal and pathological ranges and changes in the measured physiological signals

5.1 SaO2 and PaO2

The SaO2 normal range (two standard deviations (SDs) around mean) for adults aged < 70 years at sea level is 94–98%. For young adults (age 18–24), the 2SDs PaO2 range is 11.98–14.82 kPa (89.3–110.5 mmHg). The lower limit for this range decreases significantly with increasing age [152], e.g., the range for 64 years old and more is 9.02–14.76 kPa (67.3–110.1 mmHg) [47]. Additionally, the PaO2 is 0.8 kPa (6 mmHg) lower in the supine position than in the upright position.

Oxygen demand and oxygen delivery increase during exercise and reduce during rest and sleep. Hypoxemia (too low PaO2) can be defined as PaO2 below the normal lower limit, but most authors suggest values of less than 8 kPa (60 mmHg), or SaO2 of 90% [47].

The most common recommendation for patients with COPD is that oxygen is admitted if the resting awake PaO2 is less than 7.3 kPa (55 mmHg), or if it is 7.3–7.9 kPa (55–59 mmHg) in the presence of an elevated hematocrit (55%) or elevated right ventricular pressure evident from ECG [55].

5.2 PaCO2

The reference range for PaCO2 is 4.6–6.1 kPa (34–46 mmHg) for a healthy adult of 18–38 years [47]. Values above 6.1 kPa are out of the normal range, but values up to 6.7 kPa can be accomplished by holding the breath.

5.3 Body temperature

In humans, the traditional normal value for the oral temperature is around 37 °C [153]. Various parts of the body are at different temperatures, and the magnitude of the temperature difference between the parts varies with the environmental temperature [153]. There are a lot of other variables that can influence temperature measurements, such as the measurement site, time of the day, age, etc. [95].

A body temperature higher than 38.5 °C is one of the factors indicating severe exacerbations [76].

5.4 Electrocardiogram

With the development of pulmonary heart disease due to COPD, the following changes might be seen in a routine ECG [154]:
  • The P wave axis is farther right than + 75°.

  • Any of the right ventricular hypertrophy criteria.

  • Late R wave progression in precordial leads.

  • Low voltage.

  • Abnormal Q waves in the inferior or anterior leads.

  • Supraventricular arrhythmias, especially atrial tachycardia, multifocal atrial tachycardia, and atrial fibrillation.

  • Ventricular arrhythmias [155].

On the other hand, some more acutely presenting ECG changes may signal higher risk for the patient. It is known that patients with COPD have higher rates of cardiovascular diseases and consequently higher incidence of cardiovascular causes of mortality [63, 64, 65, 66].

Some ECG changes can be attributable to acute overloading of the right ventricule of the heart which may be seen in acute pulmonary embolism or acute respiratory failure, such as
  • S1Q3 pattern in standard leads.

  • Acute right bundle branch block.

  • Right axis deviation [155].

but some more subtle changes may contribute to the importance of the ECG changes in defining the risk of the patients with otherwise stable COPD:
  • Prolongation or shortening of the heart rate corrected QT interval (QTc) suggests higher incidence of sudden cardiac death. It has been shown that these changes may occur more often in patients with COPD [156].

  • Reduced heart rate variability is also a marker of sudden cardiac death and has been connected to patients with COPD.

  • Dispersion of the QT interval in ECG recordings shows potential to foresee the adverse events and has been appreciated more often in patients with COPD [157].

Supraventricular arrhythmias occur frequently in patients with COPD [63]. Most often, they comprise atrial tachycardias, especially multifocal atrial tachycardia, atrial fibrillation, and atrial undulation which are often chronic. Ventricular tachycardias such as non-sustained ventricular tachycardia may depict patient’s higher risk for adverse events. Sustained ventricular tachycardia and ventricular fibrillation are arrhythmias that need to be terminated instantaneously. Arrhythmias are in general life-threatening events and can lead to dangerous complications. For instance, patients with COPD and multifocal atrial tachycardia have higher mortality rates [158].

Cardiac arrhythmia is a group of conditions in which the heartbeat is irregular, too fast, or too slow. If a heartbeat is above 100 beats/min in adults, it is called tachycardia and a heartbeat that is below 60 beats/min is called bradycardia. To distinguish between different arrhythmia types, other diagnostic procedures must be used in addition to the HR analysis.

The ECG can show signs of myocardial ischemia, specifically ST segment and T wave changes, as well as signs of myocardial infarction, specifically changes in the QRS pattern. However, not all patients with acute or previous myocardial infarction exhibit ECG changes [159, 160].

5.5 Arterial blood pressure

“Hypertension is likely to be the most frequently occurring comorbidity in COPD and can have implications for prognosis” [30]. The pressure in the aorta and in the brachial and other large arteries in a young adult human rises to a peak value (systolic pressure) of about 120 mmHg during each heart cycle and falls to a minimum (diastolic pressure) of about 70 mmHg [161]. Conventional notation for the arterial pressure is systolic pressure over diastolic pressure, e.g. 120/70 mmHg. There are, however, a number of variables that can influence normal blood pressure values. For details, the reader is referred to [161] or similar literature.

There are different guidelines that usually define the pressure intervals specifying different hypertension severities. Stage 1 hypertension is defined as “clinical blood pressure of 140/90 mmHg or higher and subsequent ambulatory blood pressure monitoring daytime average or home blood pressure monitoring average blood pressure is 135/85 mmHg or higher” [162]. Therefore, in remote settings, we can consider 135/85 mmHg as a general threshold for hypertension.

5.6 Spirometry output

The presence of a post-bronchodilator FEV1/FVC of less than 0.70 confirms the presence of COPD [66]. The severity of COPD can be categorized based on FEV1 (percent of predicted): mild ≥ 70, moderate 50–69, severe < 50 [76], or according to GOLD: mild ≥ 80, moderate 50–79, severe 30–48, very severe < 30. For the complete list of reference values in spirometry, see [91].

5.7 Respiratory rate

One of the signs of COPD exacerbation is a respiratory rate over 25/min [76]. A normal adult human at rest breathes 12–15 times a minute [163].

6 Conclusion and future development

The guideline for home treatment and management of mild COPD exacerbations, as specified by the European Respiratory Society [76], states that patients need to be reassessed every 48 h for worsening of symptoms, signs, and measurements. With the inclusion of continuous monitoring, this interval can be prolonged and the home treatment of exacerbations made more secure.

Two crucial improvements to the current remote-monitoring systems are enabling the continuous monitoring of the most important physiological parameters and enabling real-time decision support based on advanced classification algorithms, which are still to prove their clinical reliability. This will make it possible to detect life-threatening events in real time, consequently reducing mortality and hospitalization. Other expected consequences are an increase in the cost efficiency and an improvement of patients’ compliance with the monitoring. Furthermore, continuous monitoring can provide new insights into the patients’ states, like detecting transitions from a deteriorated to the normal state that happened without an intervention, and information about the durations of the exacerbations. Moreover, the decision support algorithms can rank features by their predictive power and even create new rules, consequently enriching clinical knowledge.

All the presented devices are already mature enough to be used for remote monitoring. Only in the case of transcutaneous measurements of O2 and CO2, the high costs of the devices currently hinder them from being placed in a large proportion of COPD patients’ homes. Still, as we discussed in Sect. 4.1, they could be efficiently and usefully applied by nurses visiting patients in their homes, and shared between multiple patients.

In the future, we can expect the design of the available devices to further improve in terms of lower power usage, the batteries will have higher capacities, enabling longer stand-alone periods for wireless sensors, and the electronics will improve, enabling further minimization. The level of user acceptance should be considered even during the design time, because tailoring the systems to target groups’ specific needs, reduces technophobia, and consequently improves acceptance.

At the signal-processing level, the obtained physiological signals are usually much more contaminated with noise and artifacts in the case of remote monitoring, with respect to those obtained in hospital settings. How to remove the artifacts and noise efficiently is still an open question, and algorithms are currently being developed for this purpose, which should run efficiently on sensors or PCDs. The possibility of having a lot of wireless sensors, either worn by the subjects or placed in subjects’ environments, that can produce the data quickly (e.g. ECG, 1000 samples per second) also imposes specific challenges in the area of wireless networks, which should be able to communicate the data without significant losses, and handle the devices in a plug-and-play manner.

The sensitive nature of medical data imposes a need to ensure the privacy and security of the obtained measurements at all levels, from sensors to the cloud, and in all communication channels. This is still an open issue for which algorithms, frameworks, and standards are currently being developed.

With the future developments of all the necessary technology, we can expect remote monitoring systems for COPD, as well as for other diseases, to become integrated into the healthcare system, which will reduce costs and improve care. Additionally, remote monitoring enables the treatments and care to be tailored to each patient’s needs based on their predicted response and individual risks, which is the core requirement of personalized medicine.



The authors are grateful to MD Sinisa Ajkholt, specialist in anesthesiology, Kliniken an der Paar, Friedberg Hospital, Friedberg, Germany, for valuable advice and help.

Ivan Tomasic gratefully acknowledges the funding by the Swedish Knowledge Foundation (KKS), project name: CCOPD (reference number 20160029), and support by the Embedded sensor systems for health research profile, also funded by the KKS.

Roman Trobec acknowledges the financial support of the Slovenian Research Agency under Grant P2-0095.


  1. 1.
    (2014) The top 10 causes of death. In: World Heal. Organ. Accessed 3 Jun 2017
  2. 2.
    Klersy C, De Silvestri A, Gabutti G et al (2011) Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail 13:450–459. PubMedCrossRefGoogle Scholar
  3. 3.
    Udsen FW, Hejlesen O, Ehlers LH (2014) A systematic review of the cost and cost-effectiveness of telehealth for patients suffering from chronic obstructive pulmonary disease. J Telemed Telecare 20:212–220. PubMedCrossRefGoogle Scholar
  4. 4.
    Pare G, Poba-Nzaou P, Sicotte C et al (2013) Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: a randomized controlled trial. Eur Res Telemed 2:35–47. CrossRefGoogle Scholar
  5. 5.
    Sullivan SD, Ramsey SD, Lee TA (2000) The economic burden of COPD. Chest 117:5S–9S. PubMedCrossRefGoogle Scholar
  6. 6.
    Cordova FC, Ciccolella D, Grabianowski C et al (2015) A telemedicine-based intervention reduces the frequency and severity of COPD exacerbation symptoms: a randomized, controlled trial. Telemed e-Health 22:114–122. Google Scholar
  7. 7.
    Postma DS, Ten Hacken NH, Kerstjens H a, Koëter GH (1999) Home treatment of COPD exacerbations. Thorax 54:S8–S13.
  8. 8.
    St. George’s Respiratory Questionnaire. Accessed 1 Jun 2016
  9. 9.
    McLean S, Nurmatov U, Liu JL, Pagliari C, Car JSA (2011) Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev Jul 6:CD007718. Google Scholar
  10. 10.
    McLean S, Protti D, Sheikh A (2011) Telehealthcare for long term conditions. BMJ 342:d120.
  11. 11.
    Paré G, Jaana M, Sicotte C (2007) Systematic review of home telemonitoring for chronic diseases: the evidence base. J Am Med Informatics Assoc 14:269–277. CrossRefGoogle Scholar
  12. 12.
    Paré G, Moqadem K, Pineau G, St-Hilaire C (2010) Clinical effects of home telemonitoring in the context of diabetes, asthma, heart failure and hypertension: a systematic review. J Med Internet Res 12:e21.
  13. 13.
    Bashshur RL, Shannon GW, Smith BR et al (2014) The empirical foundations of telemedicine interventions for chronic disease management. Telemed J E Health 20:769–800. PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Lundell S, Holmner Å, Rehn B et al (2015) Telehealthcare in COPD: a systematic review and meta-analysis on physical outcomes and dyspnea. Respir Med 109:11–26. PubMedCrossRefGoogle Scholar
  15. 15.
    Pedone C, Lelli D (2015) Systematic review of telemonitoring in copd: an update. Pneumonol Alergol Pol 83:476–484. PubMedCrossRefGoogle Scholar
  16. 16.
    Pinnock H, Hanley J, McCloughan L et al (2013) Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ 347:1–16. CrossRefGoogle Scholar
  17. 17.
    McDowell JE, McClean S, FitzGibbon F, Tate S (2015) A randomised clinical trial of the effectiveness of home-based health care with telemonitoring in patients with COPD. J Telemed Telecare 21:80–87. PubMedCrossRefGoogle Scholar
  18. 18.
    Polisena J, Tran K, Cimon K et al (2010) Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Telemed Telecare 16:120–127. PubMedCrossRefGoogle Scholar
  19. 19.
    Zheng Y, Ding X, Poon C et al (2014) Unobtrusive sensing and wearable devices for health informatics. IEEE Trans Biomed Eng 61:1538–1554. PubMedCrossRefGoogle Scholar
  20. 20.
    Cruz J, Brooks D, Marques A (2014) Home telemonitoring in COPD: a systematic review of methodologies and patients’ adherence. Int J Med Inform 83:249–263. PubMedCrossRefGoogle Scholar
  21. 21.
    Sanchez-Morillo D, Fernandez-Granero MA, Leon-Jimenez A (2016) Use of predictive algorithms in-home monitoring of chronic obstructive pulmonary disease and asthma. Chron Respir Dis 13:264–283. PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Mosenifar Z (2015) Chronic obstructive pulmonary disease (COPD)—pathophysiology. In: Medscape. Accessed 1 Jan 2016
  23. 23.
    Owens RL (2013) Supplemental oxygen needs during sleep. Who benefits? Respir Care 58:32–47. PubMedCrossRefGoogle Scholar
  24. 24.
    Brill SE, Wedzicha JA (2014) Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 9:1241–1252. PubMedPubMedCentralGoogle Scholar
  25. 25.
    Bradley JM, Lasserson T, Elborn S et al (2007) A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. Chest 131:278–285. PubMedCrossRefGoogle Scholar
  26. 26.
    Han MK, Stephen C. Lazarus (2016) COPD: Clinical diagnosis and management. In: Murray Nadel’s Textb. Respir. Med., 6th ed. Elsevier Saunders, pp 767–785Google Scholar
  27. 27.
    Cranston JM, Crockett AJ, Moss JR, Alpers JH (2005) Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane database Syst Rev 19:CD001744.
  28. 28.
    Tiep BL, Carter R (2016) Long-term supplemental oxygen therapy. In: UpToDate. Accessed 1 Oct 2016
  29. 29.
    Lindford AJ, Tehrani H, Sassoon EM, O’Neill TJ (2006) Home oxygen therapy and cigarette smoking: a dangerous practice. Ann Burns Fire Disasters 19:99–100PubMedPubMedCentralGoogle Scholar
  30. 30.
    Vogelmeier CF, Criner GJ, Martinez FJ et al (2017) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report GOLD executive summary. AJRCCM Artic Press 195:201701–201218. Google Scholar
  31. 31.
    Collins J-A, Rudenski A, Gibson J et al (2015) Relating oxygen partial pressure, saturation and content : the haemoglobin – oxygen dissociation curve. Breathe 11:194–201. PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Amaddeo A, Fauroux B (2015) Oxygen and carbon dioxide monitoring during sleep. Paediatr Respir Rev 20:42-44.
  33. 33.
    Janssens JP, Borel JC, Pépin JL (2011) Nocturnal monitoring of home non-invasive ventilation: the contribution of simple tools such as pulse oximetry, capnography, built-in ventilator software and autonomic markers of sleep fragmentation. Thorax 66:438–445. PubMedCrossRefGoogle Scholar
  34. 34.
    Piquilloud L, Thevoz D, Jolliet P, Revelly J-P (2015) End-tidal carbon dioxide monitoring using a naso-buccal sensor is not appropriate to monitor capnia during non-invasive ventilation. Ann Intensive Care 5:1–8. CrossRefGoogle Scholar
  35. 35.
    Storre JH, Magnet FS, Dreher M, Windisch W (2011) Transcutaneous monitoring as a replacement for arterial PCO(2) monitoring during nocturnal non-invasive ventilation. Respir Med 105:143–150. PubMedCrossRefGoogle Scholar
  36. 36.
    Casati A, Squicciarini G, Malagutti G et al (2006) Transcutaneous monitoring of partial pressure of carbon dioxide in the elderly patient: a prospective, clinical comparison with end-tidal monitoring. J Clin Anesth 18:436–440. PubMedCrossRefGoogle Scholar
  37. 37.
    Domingo C, Canturri E, Luján M et al (2006) Transcutaneous measurement of partial pressure of carbon dioxide and oxygen saturation: validation of the SenTec monitor. Arch Bronconeumol 42:246–251. PubMedGoogle Scholar
  38. 38.
    Drysdale D (2014) Transcutaneous carbon dioxide monitoring: literature review. Oral Health Dent Manag 13:453–457. PubMedGoogle Scholar
  39. 39.
    Fruchter O, Carmi U, Ingenito EP et al (2011) Transcutaneous carbon dioxide in severe COPD patients during bronchoscopic lung volume reduction. Respir Med 105:602–607. PubMedCrossRefGoogle Scholar
  40. 40.
    Herrejón A, Inchaurraga I, Palop J et al (2006) Usefulness of transcutaneous carbon dioxide pressure monitoring to measure blood gases in adults hospitalized for respiratory disease. Arch Bronconeumol 42:225–229. PubMedCrossRefGoogle Scholar
  41. 41.
    Janssens JP, Perrin E, Bennani I et al (2001) Is continuous transcutaneous monitoring of PCO2 (TcPCO2) over 8 h reliable in adults? Respir Med 95:331–335. PubMedCrossRefGoogle Scholar
  42. 42.
    Liu S, Sun J, Chen X et al (2014) The application of transcutaneous CO2 pressure monitoring in the anesthesia of obese patients undergoing laparoscopic bariatric surgery. PLoS One 9:e91563. PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Nardi J, Prigent H, Adala A et al (2012) Nocturnal oximetry and transcutaneous carbon dioxide in home-ventilated neuromuscular patients. Respir Care 57:1425–1430. PubMedCrossRefGoogle Scholar
  44. 44.
    Hazenberg A, Zijlstra JG, Kerstjens HAM, Wijkstra PJ (2011) Validation of a transcutaneous CO2 monitor in adult patients with chronic respiratory failure. Respiration 81:242–246. PubMedCrossRefGoogle Scholar
  45. 45.
    Stege G, van den Elshout FJJ, Heijdra YF et al (2009) Accuracy of transcutaneous carbon dioxide tension measurements during cardiopulmonary exercise testing. Respiration 78:147–153. PubMedCrossRefGoogle Scholar
  46. 46.
    Chhajed PN, Miedinger D, Baty F et al (2010) Comparison of combined oximetry and cutaneous capnography using a digital sensor with arterial blood gas analysis. Scand J Clin Lab Invest 70:60–64. PubMedCrossRefGoogle Scholar
  47. 47.
    O’Driscoll BR, Howard LS, Davison a G (2008) BTS guideline for emergency oxygen use in adult patients. Thorax 63 Suppl 6:vi1–68.
  48. 48.
    Abdo WF, Heunks LMA (2012) Oxygen-induced hypercapnia in COPD: myths and facts. Crit Care 16:323. PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Plant PK, Owen JL, Elliott MW (2000) One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. Thorax 55:550–554. PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Juan G, Calverley P, Talamo C et al (1984) Effect of carbon dioxide on diaphragmatic function in human beings. N Engl J Med 310:874–879. PubMedCrossRefGoogle Scholar
  51. 51.
    Austin MA, Wills KE, Blizzard L et al (2010) Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ 341:c5462. PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Hardinge M, Annandale J, Bourne S et al (2015) British Thoracic Society guidelines for home oxygen use in adults. Thorax 70:i1–i43. PubMedCrossRefGoogle Scholar
  53. 53.
    Cooper CB, Waterhouse J, Howard P (1987) Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax 42:105–110. PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Török SS, Leuppi JD, Baty F et al (2008) Combined oximetry-cutaneous capnography in patients assessed for long-term oxygen therapy. Chest 133:1421–1425. PubMedCrossRefGoogle Scholar
  55. 55.
    Wijkstra PJ, Guyatt GH, Ambrosino N et al (2001) International approaches to the prescription of long-term oxygen therapy. Eur Respir J 18:909–913. PubMedCrossRefGoogle Scholar
  56. 56.
    Samolski D, Tárrega J, Antón A et al (2010) Sleep hypoventilation due to increased nocturnal oxygen flow in hypercapnic COPD patients. Respirology 15:283–288. PubMedCrossRefGoogle Scholar
  57. 57.
    Windisch W, Storre JH, Köhnlein T (2015) Nocturnal non-invasive positive pressure ventilation for COPD. Expert Rev Respir Med 9:295–308. PubMedCrossRefGoogle Scholar
  58. 58.
    Crimi C, Noto A, Princi P et al (2016) Domiciliary non-invasive ventilation in COPD: an international survey of indications and practices. COPD J Chronic Obstr Pulm Dis 13:483–490. CrossRefGoogle Scholar
  59. 59.
    Arnal JM, Texereau J, Garnero A (2017) Practical insight to monitor home NIV in COPD patients. COPD J Chronic Obstr Pulm Dis 14:401–410. CrossRefGoogle Scholar
  60. 60.
    Rich S (2011) Right ventricular function. Braunwald’s Hear. Dis. A Textb. Cardiovasc. Med., 9th ed. Elsevier, p 1707Google Scholar
  61. 61.
    Orchard CH, Kentish JC (1990) Effects of changes of pH on the contractile function of cardiac muscle. Am J Physiol - Cell Physiol 258:C967–C981. CrossRefGoogle Scholar
  62. 62.
    Kiely DG, Cargill RI, Lipworth BJ (1996) Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans. Chest 109:1215–1221 PubMedCrossRefGoogle Scholar
  63. 63.
    Falk JA, Kadiev S, Criner GJ et al (2008) Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5:543–548. PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Sode BF, Dahl M, Nordestgaard BG (2011) Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish Nationwide Study of 7.4 million individuals. Eur Heart J 32:2365–2375. PubMedCrossRefGoogle Scholar
  65. 65.
    Zvezdin B, Milutinov S, Kojicic M et al (2009) A postmortem analysis of major causes of early death in patients. Chest 136:376–380. PubMedCrossRefGoogle Scholar
  66. 66.
    Vestbo J, Hurd SS, Agustí AG et al (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med 187:347–365. PubMedCrossRefGoogle Scholar
  67. 67.
    Watz H, Pitta F, Rochester CL et al (2014) An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 44:1521–1537. PubMedCrossRefGoogle Scholar
  68. 68.
    Pitta F, Troosters T, Probst VS et al (2006) Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J Off J Eur Soc Clin Respir Physiol 27:1040–1055. Google Scholar
  69. 69.
    Waschki B, Kirsten A, Holz O et al (2011) Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 140:331–342. PubMedCrossRefGoogle Scholar
  70. 70.
    Andrianopoulos V, Vanfleteren LEG, Jarosch I et al (2016) Transcutaneous carbon-dioxide partial pressure trends during six-minute walk test in patients with very severe COPD. Respir Physiol Neurobiol 233:52–59. PubMedCrossRefGoogle Scholar
  71. 71.
    Miravitlles M, Ferrer M, Pont a, et al. (2004) Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59:387–395.
  72. 72.
    Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852. PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Soler-Cataluña JJ, Martínez-García MÁ, Sánchez PR et al (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925–931. PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Wilkinson TMA, Donaldson GC, Hurst JR et al (2004) Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 169:1298–1303. PubMedCrossRefGoogle Scholar
  75. 75.
    Gravil JH, Al-Rawas OA, Cotton MM et al (1998) Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet 351:1853–1855. PubMedCrossRefGoogle Scholar
  76. 76.
    Siafakas NM, Vermeire P, Pride NB et al (1995) Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 8:1398–1420. PubMedCrossRefGoogle Scholar
  77. 77.
    (2016) Radiometer Medical ApS, Transcutaneous monitoring. Accessed 1 Jan 2016
  78. 78.
    Baig MM, Gholamhosseini H, Connolly MJ (2013) A comprehensive survey of wearable and wireless ECG monitoring systems for older adults. Med Biol Eng Comput 51:485–495. PubMedCrossRefGoogle Scholar
  79. 79.
    Fung E, Järvelin MR, Doshi RN et al (2015) Electrocardiographic patch devices and contemporary wireless cardiac monitoring. Front Physiol 6:1–10. CrossRefGoogle Scholar
  80. 80.
    Guzik P, Malik M (2016) ECG by mobile technologies. J Electrocardiol 49:894–901. PubMedCrossRefGoogle Scholar
  81. 81.
    Tomasic I, Avbelj V, Trobec R (2015) Smart wireless sensor for physiological monitoring. In: Stud. Heal. Technol. Informatics, pHealth 2015. IOS press, 211:295–301.
  82. 82.
    Trobec R, Avbelj V, Stanič U, et al. (2017) System for mobile monitoring of vital functions and environmental context. Procedia Technology 27:157-158.
  83. 83.
    Yañez AM, Guerrero D, Pérez De Alejo R et al (2012) Monitoring breathing rate at home allows early identification of COPD exacerbations. Chest 142:1524–1529. PubMedCrossRefGoogle Scholar
  84. 84.
    Shah SA, Velardo C, Farmer A, Tarassenko L (2017) Exacerbations in chronic obstructive pulmonary disease: identification and prediction using a digital health system. J Med Internet Res 19:e69. PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Nemati S, Malhotra A, Clifford GD (2011) Data fusion for improved respiration rate estimation. EURASIP J Adv Signal Process 926305:1–19. Google Scholar
  86. 86.
    Charlton PH, Bonnici T, Tarassenko L et al (2016) An assessment of algorithms to estimate respiratory rate from the electrocardiogram and photoplethysmogram. Physiol Meas 37:610–626. PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Medtronic (2016) Nellcor™ Bedside Respiratory Patient Monitoring System, PM1000N. Accessed 1 Apr 2016
  88. 88.
    Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the management of arterial hypertension. Eur Heart J 28:1462–1536. PubMedGoogle Scholar
  89. 89.
    Kim S-H, Lilot M, Sidhu KS et al (2014) Accuracy and precision of continuous noninvasive arterial pressure monitoring compared with invasive arterial pressure: a systematic review and meta-analysis. Anesthesiology 120:1080–1097. PubMedCrossRefGoogle Scholar
  90. 90.
    Yilmaz T, Foster R, Hao Y (2010) Detecting vital signs with wearable wireless sensors. Sensors 10:10837–10862. PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Quanjer P, Tammeling GJ, Pedersen OF et al (1993) Lung volumes and forced ventilator flows. Eur Respir J 6:5–40. PubMedCrossRefGoogle Scholar
  92. 92.
    Derom E, Van Weel C, Liistro G et al (2008) Primary care spirometry. Eur Respir J 31:197–203. PubMedCrossRefGoogle Scholar
  93. 93.
    van den Berge M, Hop WC, van der Molen T et al (2012) Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res 13:44. PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    de la Iglesia F, Díaz JL, Pita S et al (2005) Peak expiratory flow rate as predictor of inpatient death in patients with chronic obstructive pulmonary disease. South Med J 98:266–272. PubMedCrossRefGoogle Scholar
  95. 95.
    Kelly G (2006) Body temperature variability (part 1): a review of the history of body temperature and its variability due to site selection, biological rhythms, fitness, and aging. Altern Med Rev 11:278–293PubMedGoogle Scholar
  96. 96.
    Darçın M (2014) Association between air quality and quality of life. Environ Sci Pollut Res Int 21:1954–1959. PubMedCrossRefGoogle Scholar
  97. 97.
    Salvi SS, Barnes PJ (2009) Chronic obstructive pulmonary disease in non-smokers. Lancet 374:733–743. PubMedCrossRefGoogle Scholar
  98. 98.
    Trobec R, Tomašić I (2011) Synthesis of the 12-lead electrocardiogram from differential leads. IEEE Trans Inf Technol Biomed 15:615–621. PubMedCrossRefGoogle Scholar
  99. 99.
    Trobec R, Rashkovska A, Avbelj V (2012) Two proximal skin electrodes—a respiration rate body sensor. Sensors (Switzerland) 12:13813–13828. CrossRefGoogle Scholar
  100. 100.
    Rashkovska A, Tomašić I, Bregar K, Trobec R (2012) Remote monitoring of vital functions—proof-of-concept system. In: Proc. 35th Int. conv. MIPRO. pp 446–450Google Scholar
  101. 101.
    Fairbrother P, Pinnock H, Hanley J et al (2013) Exploring telemonitoring and self-management by patients with chronic obstructive pulmonary disease: a qualitative study embedded in a randomized controlled trial. Patient Educ Couns 93:403–410. PubMedCrossRefGoogle Scholar
  102. 102.
    Majothi S, Jolly K, Heneghan NR et al (2015) Supported self-management for patients with copd who have recently been discharged from hospital: a systematic review and meta-analysis. Int J COPD 10:853–867. Google Scholar
  103. 103.
    Velardo C, Shah SA, Gibson O et al (2017) Digital health system for personalised COPD long-term management. BMC Med Inform Decis Mak 17:1–13. CrossRefGoogle Scholar
  104. 104.
    McKinstry B, Pinnock H, Sheikh A (2009) Telemedicine for management of patients with COPD? Lancet 374:672–673. PubMedCrossRefGoogle Scholar
  105. 105.
    Storre JH, Steurer B, Kabitz H-J et al (2007) Transcutaneous PCO2 monitoring during initiation of noninvasive ventilation. Chest 132:1810–1816. PubMedCrossRefGoogle Scholar
  106. 106.
    Trobec R, Tomasic I, Rashkovska A, et al. (2018) Detection of heartbeats. In: Body Sensors Electrocardiogr. Springer, pp 49–51Google Scholar
  107. 107.
    Schäfer A, Kratky KW (2008) Estimation of breathing rate from respiratory sinus arrhythmia: comparison of various methods. Ann Biomed Eng 36:476–485. PubMedCrossRefGoogle Scholar
  108. 108.
    Widjaja D, Taelman J, Vandeput S et al (2010) ECG-derived respiration: comparison and new measures for respiratory variability. Comput Cardiol 2010:149–152Google Scholar
  109. 109.
    Sankari Z, Adeli H (2011) HeartSaver: a mobile cardiac monitoring system for auto-detection of atrial fibrillation, myocardial infarction, and atrio-ventricular block. Comput Biol Med 41:211–220. PubMedCrossRefGoogle Scholar
  110. 110.
    Tomasic I, Frljak S, Trobec R (2013) Estimating the universal positions of wireless body electrodes for measuring cardiac electrical activity. IEEE Trans Biomed Eng 60:3368–3374. PubMedCrossRefGoogle Scholar
  111. 111.
    Tomasic I, Trobec R (2014) Electrocardiographic systems with reduced numbers of leads-synthesis of the 12-lead ECG. IEEE Rev Biomed Eng 7:126–142. PubMedCrossRefGoogle Scholar
  112. 112.
    Väisänen J, Puurtinen M, Hyttinen J (2010) Viik J (2010) Short distance bipolar electrocardiographic leads in diagnosis of left ventricular hypertrophy. Comput Cardiol 37:293–296Google Scholar
  113. 113.
    Puurtinen M, Väisänen J, Viik J, Hyttinen J (2010) New precordial bipolar electrocardiographic leads for detecting left ventricular hypertrophy. J Electrocardiol 43:654–659. PubMedCrossRefGoogle Scholar
  114. 114.
    Puurtinen M, Nieminen T, Kähönen M et al (2010) Value of leads V4R and CM5 in the detection of coronary artery disease during exercise electrocardiographic test. Clin Physiol Funct Imaging 30:308–312. PubMedCrossRefGoogle Scholar
  115. 115.
    Carvalho TD, Pastre CM, Moacir Fernandes de Godoy, et al. (2011) Fractal correlation property of heart rate variability in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 6:23-28.
  116. 116.
    Botsis T, Hartvigsen G (2008) Current status and future perspectives in telecare for elderly people suffering from chronic diseases. J Telemed Telecare 14:195–203. PubMedCrossRefGoogle Scholar
  117. 117.
    Krupinski E, Dimmick S, Grigsby J et al (2006) Research recommendations for the american telemedicine association. Telemed J E Heal 12:579–589. CrossRefGoogle Scholar
  118. 118.
    Maeder A, Poultney N, Morgan G, Lippiatt R (2015) Patient compliance in home-based self-care telehealth projects. J Telemed Telecare 21:439–442. PubMedCrossRefGoogle Scholar
  119. 119.
    Vorrink SNW, Kort HSM, Troosters T, Lammers J-WJ (2011) Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res 12:33. PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Arne M, Janson C, Janson S et al (2009) Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scand J Prim Health Care 27:141–147. PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Altenburg W, Wempe J, de Greef M et al (2014) Short- and long-term effects of a physical activity counselling program in COPD. Eur Respir J 44Google Scholar
  122. 122.
    Demeyer H, Louvaris Z, Frei A, et al. (2017) Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax thoraxjnl-2016-209026.
  123. 123.
    Sievi NA, Brack T, Brutsche MH et al (2017) Accelerometer- versus questionnaire-based assessment of physical activity and their changes over time in patients with COPD. Int J COPD 12:1113–1118. CrossRefGoogle Scholar
  124. 124.
    Mendoza L, Horta P, Espinoza J et al (2015) Pedometers to enhance physical activity in COPD: a randomised controlled trial. Eur Respir J 45:347–354. PubMedCrossRefGoogle Scholar
  125. 125.
    van Remoortel H, Raste Y, Louvaris Z et al (2012) Validity of six activity monitors in chronic obstructive pulmonary disease: A comparison with indirect calorimetry. PLoS One 7:1–11. Google Scholar
  126. 126.
    Guyatt G, Berman L, Townsend M et al (1987) A measure of quality of life for clinical trials in chronic lung disease. Thorax 42:773–778. PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete measure of health status for chronic airflow limitation: the St. George’s respiratory questionnaire. Am Rev Respir Dis 145:1321–1327. PubMedCrossRefGoogle Scholar
  128. 128.
    Pinnock H, Steed L, Jordan R (2016) Supported self-management for COPD: making progress, but there are still challenges. Eur Respir J 48:6–9. PubMedCrossRefGoogle Scholar
  129. 129.
    Hansel TT, Barnes PJ (2009) New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 374:744–755. PubMedCrossRefGoogle Scholar
  130. 130.
    Riekert KA, Rand CS (2002) Electronic monitoring of medication adherence: when is high-tech best? J Clin Psychol Med Settings 9:25–34. CrossRefGoogle Scholar
  131. 131.
    Hafezi H, Robertson TL, Moon GD et al (2015) An ingestible sensor for measuring medication adherence. IEEE Trans Biomed Eng 62:99–109. PubMedCrossRefGoogle Scholar
  132. 132.
    Mullard A (2015) Do you want chips with that? Nat Rev Drug Discov 14:735–737. PubMedCrossRefGoogle Scholar
  133. 133.
    Pilcher J, Shirtcliffe P, Patel M et al (2015) Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respir Res 2:e000097. PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Fortier PJ, Puntin B, Aljaroudi O (2011) Improved patient outcomes through collaborative monitoring and management of subtle behavioral and physiological health changes. Proc Annu Hawaii Int Conf Syst Sci 1–10. doi: 10.1109/HICSS.2011.236Google Scholar
  135. 135.
    Jódar-Sánchez F, Ortega F, Parra C et al (2013) Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J Telemed Telecare 19:11–17. PubMedCrossRefGoogle Scholar
  136. 136.
    Bellos CC, Papadopoulos A, Rosso R, Fotiadis DI (2014) Identification of COPD patients’ health status using an intelligent system in the CHRONIOUS wearable platform. IEEE J Biomed Heal Informatics 18:731–738. CrossRefGoogle Scholar
  137. 137.
    Ho T-W, Huang C-T, Chiu H-C et al (2016) Effectiveness of telemonitoring in patients with chronic obstructive pulmonary disease in Taiwan—a randomized controlled trial. Sci Rep 6:23797. PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Antoniades NC, Rochford PD, Pretto JJ et al (2012) Pilot study of remote telemonitoring in COPD. Telemed e-Health 18:634–640. CrossRefGoogle Scholar
  139. 139.
    Pedone C, Chiurco D, Scarlata S, Incalzi RA (2013) Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial. BMC Health Serv Res 13:82. PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    van der Heijden M, Lucas PJF, Lijnse B et al (2013) An autonomous mobile system for the management of COPD. J Biomed Inform 46:458–469. PubMedCrossRefGoogle Scholar
  141. 141.
    Jensen MH, Cichosz SL, Dinesen B, Hejlesen OK (2012) Moving prediction of exacerbation in chronic obstructive pulmonary disease for patients in telecare. J Telemed Telecare 18:99–103. PubMedCrossRefGoogle Scholar
  142. 142.
    Fernández-Granero MA, Sánchez-Morillo D, León-Jiménez A, Crespo LF (2014) Automatic prediction of chronic obstructive pulmonary disease exacerbations through home telemonitoring of symptoms. Biomed Mater Eng 24:3825–3832. PubMedGoogle Scholar
  143. 143.
    Burton C, Pinnock H, McKinstry B (2015) Changes in telemonitored physiological variables and symptoms prior to exacerbations of chronic obstructive pulmonary disease. J Telemed Telecare 21:29–36. PubMedCrossRefGoogle Scholar
  144. 144.
    Mohktar MS, Redmond SJ, Antoniades NC et al (2015) Predicting the risk of exacerbation in patients with chronic obstructive pulmonary disease using home telehealth measurement data. Artif Intell Med 63:51–59. PubMedCrossRefGoogle Scholar
  145. 145.
    Sanchez-Morillo D, Fernandez-Granero MA, Jiménez AL (2015) Detecting COPD exacerbations early using daily telemonitoring of symptoms and k-means clustering: a pilot study. Med Biol Eng Comput 53:441–451. PubMedCrossRefGoogle Scholar
  146. 146.
    Stedman JRR, Anderson HRR, Atkinson RWW, Maynard RLL (1997) Emergency hospital admissions for respiratory disorders attributable to summer time ozone episode in Great Britain. Thorax 52:958–963PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Kessler R, Faller M, Fourgaut G et al (1999) Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159:158–164. PubMedCrossRefGoogle Scholar
  148. 148.
    Clini E, Vitacca M, Foglio K et al (1996) Long-term home care programmes may reduce hospital admissions in COPD with chronic hypercapnia. Eur Respir J 9:1605–1610. PubMedCrossRefGoogle Scholar
  149. 149.
    Seemungal TA, Donaldson GC, Paul EA et al (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422. PubMedCrossRefGoogle Scholar
  150. 150.
    Osman IM, Godden DJ, Friend J a, et al. (1997) Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52:67–71.
  151. 151.
    Bourbeau J, Julien M, Maltais F et al (2003) Reduction of hospital utilization in patients with chronic obstructive pulmonary disease (a disease-specific self-management intervention). Arch Intern Med 163:585–591. PubMedCrossRefGoogle Scholar
  152. 152.
    Crapo RO, Jensen RL, Hegewald M, Tashkin DP (1999) Arterial blood gas reference values for sea level and an altitude of 1, 400 meters. Am J Respir Crit Care Med 160:1525–1531. PubMedCrossRefGoogle Scholar
  153. 153.
    Barrett KE, Barman SM, Boitano S, Brooks HL (2012) Hypothalamic regulation of hormonal functions. In: Ganong’s rev. med. Physiol., 24th ed. McGraw-hill, pp 307–321Google Scholar
  154. 154.
    Di Mino TL, Ivanov AF. Burke JR. Kowey P (2005) Electrocardiography. In: Rosendorff C (ed) Essent. Cardiol. Princ. Pract., 2nd ed. Humana Press, pp 135–136Google Scholar
  155. 155.
    Konecny T, Park JY, Somers KR et al (2016) Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 114:272–277. CrossRefGoogle Scholar
  156. 156.
    Sievi NA, Clarenbach CF, Camen G et al (2014) High prevalence of altered cardiac repolarization in patients with COPD. BMC Pulm Med 14:55.
  157. 157.
    Zulli R, Donati P, Nicosia F et al (2006) Increased QT dispersion : a negative prognostic finding in chronic obstructive pulmonary disease. Intern Emerg Med 1:279–286. PubMedCrossRefGoogle Scholar
  158. 158.
    McCord J, Borzak S (1998) Multifocal atrial tachycardia. Chest 113:203–209. PubMedCrossRefGoogle Scholar
  159. 159.
    (2000) Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21:1502–1513.
  160. 160.
    Herring N, Paterson DJ (2006) ECG diagnosis of acute ischaemia and infarction: past, present and future. QJM-Int J Med 99:219–230. CrossRefGoogle Scholar
  161. 161.
    Barrett KE, Barman SM, Boitano S, Brooks HL (2012) Arterial & arteriolar circulation. In: Ganong’s Rev. Med. Physiol., 24th ed. pp 577–579Google Scholar
  162. 162.
    National Institute for Health and Clinical Excellence (2011) Hypertension: clinical management of primary hypertension in adults (NICE clinical guideline 127).Google Scholar
  163. 163.
    Barrett KE, Barman SM, Boitano S, Brooks HL (2012) Respiratory physiology. In: Ganong’s rev. med. Physiol., 24th ed. McGraw-Hill, p 619Google Scholar

Copyright information

© The Author(s) 2018

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Division of Intelligent Future TechnologiesMälardalen UniversityVästeråsSweden
  2. 2.Department of Clinical SciencesLund UniversityLundSweden
  3. 3.Department of NeonatologyKarolinska University HospitalStockholmSweden
  4. 4.Department of Communication SystemsJozef Stefan InstituteLjubljanaSlovenia
  5. 5.Department of CardiologyUniversity Hospital CentreZagrebCroatia
  6. 6.Department of Physiology, School of MedicineUniversity of ZagrebZagrebCroatia

Personalised recommendations